@Abdi70 yes there is no direct comparison at the moment until there is a RCT done. I think that there is a clear OS advantage using OncoSil. It makes sense that you deliver radiation in a localised manner vs external beam radiation. Plenty of data about external radiation having too many side effects for the poor sick pancreatic cancer patients. but you will only truly know this with the full RCT done with the FDA. The EU approves medical devices earlier, see Sirtex Medical as the precedent on this style of study. Not fully know yet but strong early evidence, hard to say a scam.
@countrychick this is a study of FOLFORINOX chemotherapy. I wrote about this earlier as this is a study of a very strong but toxic(lots of side effects) chemotherapy. Only the healthier early stage patients can tolerate this chemotherapy so this smaller patient subset that are healthy will always have a much longer OS.
Standard of care is Abraxane (much less toxic chemotherapy, new in the last couple of years) and Gemicitbine. We don't have published data yet on the use of external beam radiation to this chemotherapy arm but if OncoSil does a RCT and repeats this OS advantage this will be the new standard of care used in conjunction with Abraxane
OSL Price at posting:
6.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)